Ustekinumab is effective for maintaining clinical response in refractory moderate-to-severe crohn's disease: A Multicentre cohort study
- C. Ma
- , R. Fedorak
- , G. G. Kaplan
- , L. A. Dieleman
- , S. Devlin
- , N. Stern
- , K. I. Kroeker
- , C. Seow
- , Y. Leung
- , K. L. Novak
- , B. P. Halloran
- , V. Huang
- , K. Wong
- , S. Ghosh
- , R. Panaccione
- University of Calgary
- University of Alberta
Research output: Contribution to journal › Article › peer-review